HomeAI · summaries
Storia in 6 fonti
Sionna Therapeutics stock falls 92% after SION-719 trial failure
The biotech said it will not advance SION-719 as an add-on therapy after the drug missed its key endpoint in a Phase 2a study
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.
- ·
statnews.com
Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
A pill from Sionna Therapeutics provided no added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta, a blow to the biotech.
